Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific...
Reexamination Certificate
2002-07-25
2009-02-10
Le, Emily M. (Department: 1648)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
C435S006120, C514S025000
Reexamination Certificate
active
07488491
ABSTRACT:
The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes glycosylceramide, preferably α-galactosylceramide (α-GalCer). According to the present invention, the use of glycosylceramide as an adjuvant is attributed at least in part to the enhancement and/or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses. The methods and compositions of the present invention can be useful for prophylaxis and treatment of various infectious and neoplastic diseases.
REFERENCES:
patent: 6555375 (2003-04-01), Golovko
patent: 1 018 548 (2000-07-01), None
patent: WO-99/15627 (1999-04-01), None
Gonzalez-Aseguinolaza et al. alpha-Galactosylceramide-activated Valpha14 natural killer T cells mediate protection against murine malaria. PNAS, Jul. 18, 2000, vol. 97, No. 15, pp. 8461-8466.
Orange et al. Viral evasion of natural killer cells. Review: Nature Immunology, Vo. 3, No. 11, 2002, pp. 1006-1012.
Tsuji et al. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. Journal of Virology, 1998, vol. 72, No. 8, pp. 6907-6910.
Giaccone et al. A phase I study of the Natural Killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clinical Cancer Research, 2002, vol. 8, pp. 3702-3709.
Tsuji et al. Recombinant Sindbis viruses expressing a cytotoxic T-Lymphoctye epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. Journal of Virology, Aug. 1998, V. 72, No. 8, p. 6907-6910.
Rodrigues et al. Single immunization dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. The Journal of Immunology, 1997, vol. 158, p. 1268-1274.
Gonzalez-Aseguinolaza et al. alpha-galactosylceramide-activated Valpha14 natural killer T cells mediate protection against murine malaria. PNAS, Jul. 18, 2000; vol. 97, No. 15, p. 8461-8466.
S. Ishihara et al., “Alpha-Glycosylceramides Enhance the Antitumor Cytotoxicity of Hepatic Lymphocytes Obtained from Cancer Patients by Activating CD3-CD56+ NK Cells In Vitro,”The Journal of Immunology,2000, vol. 165, pp. 1659-1664.
Gonzalez-Aseguinolaza et al., “Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines”, J. Exp. Med., 2002, 195:617-624.
Hidemitsu Kitamura et al., “The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells,”J. Exp. Med.189(7):1121-1127 (Apr. 5, 1999).
Olivier Adotevi, at al., “B Subunit of Shiga Toxin-Based Vaccines Synergize with α-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity1,”The Journal of Immunology ,2007, 179, p. 3371-3379.
Takeshi Kinjo, et al., “NKT cells play a limited role in the neutrophilic inflammatory responses and host defense to pulmonary infection withPseudomonas aeruginosa,” Microbes and Infection2006, 8, p. 2679-2685.
Dan H. Barouch, et al., “Augmentation and Suppression of Immune Responses to an HIV-1 DNA Vaccine by Plasmid Cytokine/lg Administration,”The Journal of Immunology,1998, 161, p. 1875-1882.
Hsin-Wei Chen, et al., “Suppression of Immune Response and Protective Immunity to a Japanese Encephatilis Virus DNA Vaccine by Coadministration of an IL-12-Expressing Plasmid,”The Journal of Immunology,2001, 166, p. 7419-7426.
Cristina T. Fonseca, et al., “Co-administration of plasmid expressingIL-12with 14-kDaSchistosoma mansonifatty acid-binding protein cDNA alters immunie response profiles and fails to enhance protection induced by Sm14 DNA vaccine alone,”Microbes and Infection2006, 8, p. 2509-2516.
Phillip Scott, et al., “IL-12 as an adjuvant for cell-mediated immunity,”Seminars in Immunology,1997, 9, p. 285-291.
Luis C. C. Afonso, et al., “The Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania major,”Science,1994, 263, p. 235-237.
Yen-Hung Chow, et al., “Improvement of Hepatitis B Virus DNA Vaccines by Plasmids Coepressing Hepatitis B Surface Antigen and Interleukin-2,”Journal of Virology,1997, 71, p. 169-178.
Jan. 2008 Manuscript entitled “Enhancement of HIV DNA vaccine immunogenicity by the NK T Cell Ligand, alpha-galactosylceramide”.
Gonzalez-Aseguinolaza Gloria
Koezuka Yasuhiko
Tsuji Moriya
Darby & Darby P.C.
Le Emily M.
New York University
LandOfFree
Use of glycosylceramides as adjuvants for vaccines against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of glycosylceramides as adjuvants for vaccines against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of glycosylceramides as adjuvants for vaccines against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4131327